Study shows cancer vaccines led to long-term survival for patients with metastatic melanoma

July 28, 2009

Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.

The study entitled "Phase II Trial of Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Anti-Tumor Vaccines in Patients with Metastatic Melanoma," was published in the June 2009 issue of Cancer Biotherapy and Radiopharmaceuticals and was sponsored by Hoag Hospital Foundation.

"There is continued interest in developing new therapies for melanoma patients with recurrent or distant metastatic disease at the time of diagnosis because there are no systemic therapies that can be relied upon to cure them," said Robert O. Dillman, M.D., F.A.C.P., executive medical and scientific director at the Hoag Cancer Center and lead investigator for the study. "Patients with metastatic melanoma are at high risk for additional metastases and death."

During the study, 54 patients with regionally recurrent or distant metastatic melanoma were injected with a vaccine that included each patient's own (dendritic cells) and 500 micrograms of granulocyte-colony stimulating factor (GM-CSF), an immune stimulator, three times a week and then monthly for five months for a total of up to eight injections. The patient's dendritic cells were obtained from their peripheral blood and mixed with a cell culture of the patient's own melanoma cells that had been self-renewing and proliferating in the laboratory. The patient-specific vaccine is designed to stimulate the patient's immune system to react against tumor or early that can create new depots of cancer throughout the body.

Data showed that the projected five-year survival rate is 54% at a median follow up of 4.5 years (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results are superior to those observed following vaccination with irradiated tumor in 48 melanoma patients in a previous trial (64 vs. 31 months, p=.016). Eight patients in the dendritic cell vaccine study experienced remarkable long-term, progression-free survival after completing the vaccine therapy, even though they had widely metastatic disease and/or repeated appearance of new metastases despite various therapies. The vaccine treatment was well-tolerated, with most patients experiencing mild skin irritation and redness at the injection site.

"The one-year and projected five-year survival rates of 85% and 54%, respectively, are remarkable for melanoma patients with documented metastatic disease," said Dr. Dillman. "This study is extremely encouraging and shows the potential these types of personalized cancer vaccines have for patients diagnosed with ."

Source: Hoag Memorial Hospital Presbyterian

Explore further: Inducing melanoma for cancer vaccine development

Related Stories

Inducing melanoma for cancer vaccine development

March 27, 2006

Cancer vaccines are being investigated in early-phase clinical trials around the world, with many of those trials recruiting patients with melanoma. Although tumor regressions have been seen in 10% to 20% of patients with ...

New combination therapy safe, promising for melanoma patients

June 1, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American ...

Vaccine shows therapeutic promise against advanced melanoma

June 1, 2009

A vaccine for one of the most lethal cancers, advanced melanoma, has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2, according to researchers ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.